Literature DB >> 19038767

Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma.

Olivier Mir1, Stanislas Ropert, François Goldwasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19038767     DOI： 10.1016/S1470-2045(08)70309-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

Review 1.  Methotrexate for high-grade osteosarcoma in children and young adults.

Authors:  Elvira C van Dalen; Jorrit W van As; Beatriz de Camargo
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

2.  Long noncoding RNA ATB promotes osteosarcoma cell proliferation, migration and invasion by suppressing miR-200s.

Authors:  Feng Han; Changhe Wang; Yi Wang; Liang Zhang
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

3.  Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1.

Authors:  Chibo Liu; Jianjun Lin
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

4.  Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.

Authors:  Wei Zhang; Qing Zhang; Ting-Ting Zheng; Jian-Cun Zhen; Xiao-Hui Niu
Journal:  Chin Med J (Engl)       Date:  2016-11-05       Impact factor: 2.628

5.  Direct conversion of osteosarcoma to adipocytes by targeting TNIK.

Authors:  Toru Hirozane; Mari Masuda; Teppei Sugano; Tetsuya Sekita; Naoko Goto; Toru Aoyama; Takato Sakagami; Yuko Uno; Hideki Moriyama; Masaaki Sawa; Naofumi Asano; Masaya Nakamura; Morio Matsumoto; Robert Nakayama; Tadashi Kondo; Akira Kawai; Eisuke Kobayashi; Tesshi Yamada
Journal:  JCI Insight       Date:  2021-02-08

Review 6.  Evidence-Based Criteria Supporting Early Discharge for Pediatric Patients With Osteosarcoma Receiving High-Dose Methotrexate: A Retrospective Chart Review.

Authors:  Erin Armideo; Shannon Froio; Meredith Johnson; Alison Tardino-Gingrich; Elizabeth Froh
Journal:  J Adv Pract Oncol       Date:  2022-03-25

7.  More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate.

Authors:  Lu Xie; Wei Guo; Yi Yang; Tao Ji; Jie Xu
Journal:  Oncotarget       Date:  2017-12-14

8.  The multidisciplinary treatment of osteosarcoma of the proximal tibia: a retrospective study.

Authors:  Junqi Huang; Wenzhi Bi; Gang Han; Jinpeng Jia; Meng Xu; Wei Wang
Journal:  BMC Musculoskelet Disord       Date:  2018-09-05       Impact factor: 2.362
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.